Do you need to cycle peptides?
In 1978, a team in Pittsburgh gave the same hormone to monkeys two different ways. One way switched the reproductive system on. The other switched it off. That experiment is still the best place to start on peptide cycling.
Free to join · One email when peptide care opens · Most lab results in 3–5 business days
The answer, in short
Some peptides lose effect with constant use and some do not, so there is no single rule. Continuous GnRH and kisspeptin shut down the hormones they first raise, and the growth hormone response to hexarelin fell about 45 percent over 16 weeks, then recovered after a four-week break. Other compounds held their effect for a year. For GLP-1 medicines, stopping led to weight regain.
Medically reviewed by Robert Lufkin, MD (opens in a new tab)
Chief Medical Officer, Vitals Vault · Updated · 14 sources
Same hormone, opposite result
Ernst Knobil’s lab was studying rhesus monkeys whose hypothalamus had been damaged so it could no longer send GnRH, the signal that tells the pituitary to release the reproductive hormones LH and FSH. Without that signal, the pituitary fell silent. The question was simple. If you replace GnRH from outside, does the pituitary wake up?
It depended entirely on how the GnRH arrived. Given as a pulse once an hour, which matches the natural rhythm in monkeys, it restored gonadotropin secretion. Given as a steady infusion, it failed to. And in monkeys whose pituitaries had been revived by pulses, switching to a constant infusion shut them down again. The authors put it plainly. The effect came from the pattern of delivery, not the amount of hormone.
That finding has shaped reproductive medicine ever since. Pulsed GnRH is used to restart the reproductive axis in men and women whose hypothalamus has gone quiet, and in men with hypothalamic failure it brought LH and FSH into the normal range within a week. It also sits behind the question people ask about every peptide they take for more than a few weeks. Will it keep working, and do I need a break?12
Why a receptor stops listening
Most peptide signals land on a family of receptors called G protein-coupled receptors. They sit in the cell membrane, and when a peptide binds, they pass the message inward. Cells also have a built-in volume knob for these receptors, because a signal that never turns off is usually a sign that something is wrong.
When a receptor is switched on, enzymes called G protein-coupled receptor kinases tag it with phosphate groups. Proteins called arrestins then bind to the tagged receptor and block it from passing on further signals. Many receptors are then pulled inside the cell, away from the surface. Pharmacologists call the short-term version desensitization, and the clinical version, where a drug loses its effect with repeated use, tachyphylaxis.
This system is why rhythm matters so much. Your own hormones mostly arrive in pulses, with quiet gaps that give receptors time to reset. A peptide that floods a receptor around the clock can push it into a protective shutdown. A peptide that comes and goes may never trigger it. Whether that happens depends on the receptor, the peptide, how long it lasts in the blood and how often it is given.31
What the studies show, peptide by peptide
The idea of cycling peptides comes from online protocols, and most of them borrow a calendar from bodybuilding, several weeks on and a few off. The research tells a more specific story. Some signals fade, some hold and one gets worse when you stop. The table collects the human studies behind several profiles in this guide.
Two cautions apply when reading it. Most of these studies were small, often a dozen people or fewer, and many ran for days or weeks. And the doses and delivery methods differ from study to study, from hourly pumps to infusions to injections. What carries over is the pattern, which signals proved sensitive to constant exposure and which did not, more than any schedule a person could copy.
| Peptide or drug | With constant or repeated use | What kept or restored the effect | Study |
|---|---|---|---|
| GnRH (gonadorelin) | Continuous infusion failed to restore, and then shut down, LH and FSH | Hourly pulses | Belchetz, 1978 |
| Kisspeptin-10 | Five days of continuous infusion left LH and FSH no higher than placebo | Daily infusions for part of each day held for 12 days | Yeung, 2026 |
| Kisspeptin-54 | Twice-daily dosing caused complete tolerance in women | Twice-weekly dosing held for 8 weeks with partial desensitization | Jayasena, 2010 |
| Hexarelin | Growth hormone response about 45 percent lower by week 16 | Fully recovered after a 4-week break | Rahim, 1998 |
| GHRP-2 | Fading depended on dose and frequency | Not tested | Bowers, 1996 |
| CJC-1295 with DAC | Near-continuous GHRH signal | Natural growth hormone pulses persisted | Ionescu, 2006 |
| MK-677 (oral, non-peptide) | IGF-1 stayed in the young-adult range for a year | No break needed in the trial | Nass, 2008 |
| Semaglutide (GLP-1) | Weight kept falling with continued use | Stopping led to regain | Rubino, 2021 |
The reproductive axis listens to rhythm
Kisspeptin sits one step above GnRH and sets the pace of its pulses, so it is no surprise that it behaves the same way. In women with hypothalamic amenorrhea, twice-daily kisspeptin-54 led to complete tolerance, with the hormone response gone. Spacing the doses to twice a week caused only partial desensitization, and after eight weeks those women still had significantly higher reproductive hormones than women given saline.
A 2026 Imperial College study in 15 healthy men showed the pattern again with kisspeptin-10. Five days of continuous infusion under the skin left LH and FSH no higher than placebo, although testosterone stayed raised. Daily infusions running for part of each day kept gonadotropins up for 12 days, and at the end the receptor still answered a fresh dose.
The lesson for this axis is about rhythm within the day or week, more than breaks of several weeks. The receptor needed quiet hours, and a well-spaced pattern kept it responsive. Nobody has shown that a month off fixes a schedule that was too frequent to begin with.541
Growth hormone peptides fade, partly and reversibly
The growth hormone releasing peptides are where cycling advice is loudest, and there is real data behind some of it. In 1998, Rahim and Shalet gave 12 healthy older adults hexarelin injections twice a day for 16 weeks and measured the growth hormone response along the way. Most of the drop came early. The response was about 31 percent lower after one week and about 45 percent lower by week 16. Four weeks after stopping, a fresh dose produced a response no different from the first one. The authors called the attenuation partial and reversible.
That is the clearest human evidence that a break can restore a fading peptide. It is also narrower than it sounds. Shorter courses of 8 to 15 days, by nose or mouth, did not blunt the response in older adults. For GHRP-2, a 1996 study found that whether the response faded depended on the dose and how often it was given.
Other members of the family held up. CJC-1295 with DAC, which binds albumin and gives the pituitary a near-continuous GHRH signal, did not flatten natural growth hormone pulses in healthy young men. MK-677, an oral compound acting on the same ghrelin receptor as hexarelin, kept growth hormone and IGF-1 in the range of healthy young adults over a year of daily use. In a 16-week GHRH analog study, by contrast, IGF-1 drifted back toward baseline by the end.
Why would two compounds that act on the same receptor behave so differently? The studies do not settle it. One possibility is the shape of the exposure, sharp injected spikes in one case and a gentler daily oral dose in the other. The people studied also differed, and neither trial was designed to compare the two. The safe reading is that durability belongs to a specific molecule given a specific way. Results from one member of the family do not transfer to its relatives.67891011
When a break backfires
Cycling assumes the main risk is a signal wearing out. For some peptides the bigger risk is the opposite, that the effect only lasts while the signal is there.
The GLP-1 medicines are the best-studied example. In the STEP 4 trial, 803 adults who had lost an average of 10.6 percent of their body weight over 20 weeks on semaglutide were randomized to keep going or switch to placebo. Over the next 48 weeks, those who continued lost another 7.9 percent. Those switched to placebo regained 6.9 percent. The drug had not stopped working. It had been holding the weight down, and taking it away let the weight return.
A break, in other words, is a test of whether a result depends on the drug. For a hormone axis that has gone numb, a break can restore it. For a chronic condition held in check by a medicine, a break mostly shows you how much work the medicine was doing.12
How to know whether a peptide is fading
Feelings are a poor gauge of desensitization, because the slide is gradual and often happens in the first week or two, before anyone has settled into a routine. The hexarelin study only saw the fade because it measured growth hormone directly at set points.
Blood tests do the same job in practice. For growth hormone peptides, IGF-1 at baseline and on treatment shows whether the signal is landing, and a falling value on an unchanged plan is the first sign of fade. Fasting glucose and HbA1c belong alongside it, since this family can raise blood sugar. For reproductive peptides, LH, FSH and testosterone or estradiol, timed with your clinician, show whether the axis is still answering.
If a marker drifts, the evidence points to a few options worth discussing with your clinician, including spacing doses further apart, a planned break or switching to a molecule with a different profile. The point is to let your numbers make the call, rather than a calendar borrowed from someone else.61110
Where regulation stands
Since October 29, 2026, FDA allows 503A pharmacies to compound BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax with a prescription, under enforcement discretion while final rulemaking is pending. None of the six is FDA-approved, so there is no labeled guidance on cycling for any of them. The schedule is set by the prescribing clinician.1314
What it means for you
Do you need to cycle peptides? For some, the evidence says rhythm matters a great deal. GnRH and kisspeptin shut down under constant exposure and work when pulsed. The hexarelin response faded within weeks and came back after a month off. For others, the data show steady effects over a year, and for GLP-1 medicines a break mostly brings the weight back.
So the useful question is which peptide, given how, for what goal. A blanket rule of several weeks on and a few off has no study behind it. Spacing within the week often matters more than long breaks, and a lab marker will tell you more than any calendar.
Ask your clinician this. What marker will show us if this stops working, when will we check it, and what will we change if it does? That plan, built around your own numbers, is the version of cycling the evidence supports.1461012
Start with your labs
A blood test before you start and a retest after shows what actually changed for you. It is how Vitals Vault approaches every treatment.
- TestA baseline panel at Quest Diagnostics.
- DecideA licensed clinician reviews your history and results.
- RetestThe same markers again, side by side.
Questions
Do you need to cycle peptides?
It depends on the peptide. GnRH and kisspeptin lose effect with constant exposure and work best in pulses. The hexarelin response faded over 16 weeks and recovered after a four-week break. Other compounds held up for a year, and stopping GLP-1 medicines led to weight regain.
What is peptide desensitization?
When a receptor is switched on repeatedly, cells tag it and block it from signaling, and may pull it inside the cell. The response to the same peptide then shrinks. Clinicians call loss of effect with repeated use tachyphylaxis.
Do growth hormone peptides stop working?
Some fade. In a 16-week study, the growth hormone response to hexarelin fell about 45 percent and returned after a four-week break. Fading with GHRP-2 depended on dose and frequency. An oral compound acting on the same receptor kept IGF-1 raised for a year.
How long should a peptide break be?
Only one human study has tested a break directly. After 16 weeks of hexarelin, the response had fully recovered four weeks after stopping. For other peptides there is no evidence for a specific break length, so a clinician sets it from your labs.
Should you cycle BPC-157?
No human study has tested whether BPC-157 loses effect with repeated use or whether breaks help. Courses are usually defined by the injury and a rehab plan, and a clinician sets the length.
Do you need to cycle GLP-1 medicines?
No. In the STEP 4 trial, people who stayed on semaglutide kept losing weight, while those switched to placebo regained 6.9 percent of body weight over 48 weeks. Breaks are not part of how these medicines are studied or prescribed.
How can I tell if a peptide has stopped working?
Blood tests are more reliable than how you feel. IGF-1 for growth hormone peptides, and LH, FSH and testosterone or estradiol for reproductive peptides, show whether the signal is still landing. A falling value on an unchanged plan is the first clue.
Peptides, prescribed and measured
Vitals Vault is opening peptide care that starts with your blood work, is prescribed by licensed US clinicians and ends with a retest. Join the waitlist to hear first.
- Prescription only
- Licensed US clinicians
- Quest Diagnostics labs
Keep reading
Full Peptide Guide- GonadorelinSynthetic GnRH, the hypothalamic signal that tells the pituitary to release LH and FSH.
- Kisspeptin-10The shortest active piece of kisspeptin, the brain signal that switches on the reproductive hormone axis.
- HexarelinA potent six-amino-acid ghrelin-receptor agonist studied for growth hormone release and heart function.
- GHRP-2A six-amino-acid ghrelin-receptor agonist that triggers a sharp pulse of growth hormone. Used in Japanese diagnostic research.
- CJC-1295A long-acting growth hormone releasing hormone analog, studied for raising growth hormone and IGF-1.
- MK-677An oral, non-peptide ghrelin-receptor agonist that raises growth hormone and IGF-1. FDA lists a heart failure concern.
- Peptide results timelineWhen will I see results from peptides? Hormones answer in minutes, labs in weeks, body composition in months and tendons on a clock of their own.
Sources
- 1. Belchetz PE, et al. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science. 1978 (opens in a new tab)
- 2. Hoffman AR, et al. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med. 1982 (opens in a new tab)
- 3. Gainetdinov RR, et al. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci. 2004 (opens in a new tab)
- 4. Yeung AC, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol. 2026 (opens in a new tab)
- 5. Jayasena CN, et al. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea. Clin Pharmacol Ther. 2010 (opens in a new tab)
- 6. Rahim A, et al. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998 (opens in a new tab)
- 7. Ghigo E, et al. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Eur J Endocrinol. 1996 (opens in a new tab)
- 8. Bowers CY, et al. GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab. 1996 (opens in a new tab)
- 9. Ionescu M, et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 (opens in a new tab)
- 10. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008 (opens in a new tab)
- 11. Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997 (opens in a new tab)
- 12. Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021 (opens in a new tab)
- 13. NCPA. FDA grants enforcement discretion for compounding six peptides. October 29, 2026 (opens in a new tab)
- 14. FDA. Bulk drug substances used in compounding under section 503A (opens in a new tab)